These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23098650)

  • 1. Impact of variants within seven candidate genes on statin treatment efficacy.
    Vrablík M; Hubáček JA; Dlouhá D; Lánská V; Rynekrová J; Zlatohlávek L; Prusíková M; Ceška R; Adámková V
    Physiol Res; 2012; 61(6):609-17. PubMed ID: 23098650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Willrich MA; Arazi SS; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
    Lipids Health Dis; 2011 Nov; 10():206. PubMed ID: 22074026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic hypercholesterolemia: examples of GWAS results and their replication in the Czech-Slavonic population.
    Hubacek JA; Adamkova V; Lanska V; Dlouha D
    Physiol Res; 2017 Apr; 66(Suppl 1):S101-S111. PubMed ID: 28379035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
    Luo H; Zhang X; Shuai P; Miao Y; Ye Z; Lin Y
    J Genet; 2017 Dec; 96(6):985-992. PubMed ID: 29321358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
    Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
    Hubacek JA; Dlouha D; Adámkova V; Lanska V; Ceska R; Vrablik M
    Neuro Endocrinol Lett; 2012; 33 Suppl 2():22-5. PubMed ID: 23183505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Atherosclerosis; 2005 Jun; 180(2):407-15. PubMed ID: 15910869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study.
    Farsang C; Athyros V; Gaw A;
    Curr Med Res Opin; 2007 Aug; 23(8):1945-56. PubMed ID: 17626713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
    Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
    Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
    Farnier M; Portal JJ; Maigret P
    J Cardiovasc Pharmacol Ther; 2000 Jan; 5(1):27-32. PubMed ID: 10687671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
    Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
    DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
    Wolffenbuttel BH; Mahla G; Muller D; Pentrup A; Black DM
    Neth J Med; 1998 Apr; 52(4):131-7. PubMed ID: 9646621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
    Hopewell JC; Parish S; Offer A; Link E; Clarke R; Lathrop M; Armitage J; Collins R;
    Eur Heart J; 2013 Apr; 34(13):982-92. PubMed ID: 23100282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
    Kajinami K; Brousseau ME; Ordovas JM; Schaefer EJ
    Am J Cardiol; 2004 Jan; 93(1):104-7. PubMed ID: 14697480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
    Gentile S; Turco S; Guarino G; Sasso CF; Amodio M; Magliano P; Salvatore T; Corigliano G; Agrusta M; De Simone G; Gaeta I; Oliviero B; Torella R
    Diabetes Obes Metab; 2000 Dec; 2(6):355-62. PubMed ID: 11225965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.